Bertram Glass
Overview
Explore the profile of Bertram Glass including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
3251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liebers N, Boumendil A, Finel H, Edelmann D, Kobbe G, Baermann B, et al.
Blood Cancer Discov
. 2025 Feb;
PMID: 39913291
Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an...
2.
Baertsch M, Schlenzka J, Hielscher T, Raab M, Sauer S, Merz M, et al.
Blood
. 2025 Jan;
PMID: 39808798
The multicenter, phase III GMMG ReLApsE trial (EudraCT-No:2009-013856-61) randomized relapsed and/or refractory multiple myeloma (RRMM) patients equally to lenalidomide/dexamethasone (LEN/DEX, 25mg days 1-21/40mg weekly, 4-week cycles) re-induction, salvage high dose...
3.
Tournilhac O, Altmann B, Friedrichs B, Bouabdallah K, Leclerc M, Cartron G, et al.
J Clin Oncol
. 2024 Sep;
42(32):3788-3794.
PMID: 39270145
JCO Primary analysis of the phase III randomized AATT study showed that younger patients with peripheral T-cell lymphoma (PTCL) consolidated with autologous or allogeneic transplantation (alloSCT) had similar event-free survival...
4.
Renders S, Ngoya M, Finel H, Rubio M, Townsend W, Schroers R, et al.
Blood Adv
. 2024 Aug;
8(21):5571-5578.
PMID: 39213423
Although broadly used, consolidative autologous hematopoietic stem cell transplantation (auto-HCT) for relapsed/refractory (R/R) T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) has never been specifically investigated. Here, we have analyzed outcomes of auto-HCT...
5.
Iqbal M, Kumar A, Dreger P, Chavez J, Sauter C, Sureda A, et al.
Transplant Cell Ther
. 2024 Jul;
30(9):832-843.
PMID: 38972511
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL), accounting for nearly one-third of all NHL. The therapeutic landscape for patients with FL has significantly expanded over...
6.
Berning P, Fekom M, Ngoya M, Goldstone A, Dreger P, Montoto S, et al.
Blood Cancer J
. 2024 Jul;
14(1):106.
PMID: 38969655
Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies. We examined...
7.
Montoro J, Ngoya M, Kulagin A, Giebel S, Broers A, Bramanti S, et al.
Blood Adv
. 2024 May;
8(15):3985-3992.
PMID: 38810260
Studies comparing the efficacy of posttransplant cyclophosphamide (PTCy) to conventional calcineurin inhibitor (CNI)-based graft-versus-host disease (GVHD) prophylaxis regimens in patients with Hodgkin lymphoma (HL) are scarce. This study aimed to...
8.
Abramson J, Solomon S, Arnason J, Johnston P, Glass B, Bachanova V, et al.
Future Oncol
. 2024 Mar;
20(21):1455-1465.
PMID: 38547003
No abstract available.
9.
Oertel M, Ziepert M, Frontzek F, Nacke N, Altmann B, Nickelsen M, et al.
Leukemia
. 2024 Mar;
38(5):1099-1106.
PMID: 38538861
The role of consolidative radiotherapy (RT) for patients with aggressive B-cell lymphoma has not been fully elucidated. The R-MegaCHOEP trial investigated the use of high-dose chemotherapy and rituximab with subsequent...
10.
Passweg J, Baldomero H, Ciceri F, de la Camara R, Glass B, Greco R, et al.
Bone Marrow Transplant
. 2024 Mar;
59(6):803-812.
PMID: 38438647
In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 patients received advanced cellular therapies, 3205 of which were...